公开(公告)号：US20250064920A1

公开(公告)日：2025-02-27

申请号：US18790098

申请日：2024-07-31

Applicant: Boehringer Ingelheim Vetmedica GmbH

Inventor： Grace Albanese ,  Aemro KASSA ,  Annika KRAEMER-KUEHL ,  Stephane LEMIERE

IPC: A61K39/215 ,  A61K9/00 ,  A61K39/00 ,  A61P31/14 ,  C07K14/005 ,  C12N7/00

Abstract: The present invention relates i.a. to an IBV (infectious bronchitis virus) encoding for a heterologous DMV S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said IBV encoding for a heterologous DMV S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

公开(公告)号：US12234472B2

公开(公告)日：2025-02-25

申请号：US18047341

申请日：2022-10-18

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Michael Goren ,  Yu Zhao ,  Alexandros Strikoudis ,  Darya Burakov ,  Gang Chen

IPC: C12N15/85 ,  C07K14/005 ,  C12N15/67

Abstract: The present inventions provide eukaryotic cells, such as mammalian cells, that comprise adeno-associated virus (AAV) polynucleotides, including AAV capsid proteins (Cap), and are capable of expressing the polypeptides encoded by the AAV polynucleotides, and thereby are capable of producing AAV, including recombinant AAV. The eukaryotic cells also may comprise adenovirus (Ad) polynucleotides. The present inventions also provide methods of expressing AAV polynucleotides, as well as Ad polynucleotides, in eukaryotic cells, such as CHO cells, HEK 293 and BHK cells. The present inventions further provides other products and methods described herein.

公开(公告)号：US12233123B2

公开(公告)日：2025-02-25

申请号：US18512751

申请日：2023-11-17

Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

Inventor： Peter Palese ,  Adolfo Garcia-Sastre ,  Megan Ermler ,  Florian Krammer

IPC: A61K39/145 ,  A61K35/76 ,  A61K39/00 ,  A61K39/12 ,  C07K14/005 ,  C07K14/11

Abstract: Provided herein are chimeric hemagglutinin (HA) polypeptides and uses thereof for inducing an immune response (e.g., an antibody response) against influenza virus. Also provided herein are methods of generating antibodies to the chimeric HA polypeptides in a subject.

公开(公告)号：US20250059239A1

公开(公告)日：2025-02-20

申请号：US18720534

申请日：2022-12-16

Applicant: Sana Biotechnology, Inc.

Inventor： Christopher BANDORO ,  Lauren Pepper MACKENZIE ,  Jagesh Vijaykumar SHAH ,  Kyle Marvin TRUDEAU

IPC: C07K14/005 ,  C12N15/86

Abstract: Provided herein are lipid particles, such as lentiviral particles, that incorporate or are pseudotyped with a variant Nipah Virus F (NiV-F) envelope glycoprotein, and in some aspects also an attachment glycoprotein (G) protein such as a NiV-G protein or a biologically active portion or variant thereof. Also provided are polynucleotides encoding the variant NiV-F and producer cells for preparation of the lipid particles, such as lentiviral particles, containing the variant NiV-F proteins, as well as methods for preparing and using the lipid particles, such as lentiviral particles.

公开(公告)号：US12227755B2

公开(公告)日：2025-02-18

申请号：US17846817

申请日：2022-06-22

Applicant: UNIVERSITÄT ZÜRICH

Inventor： Daniel D. Pinschewer ,  Lukas Flatz ,  Andreas Bergthaler ,  Rolf Zinkernagel

IPC: C12N15/86 ,  A61K35/76 ,  A61K39/12 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III. The modified arenaviruses are useful as vaccines and therapeutic agents for a variety of diseases.

公开(公告)号：US12226472B2

公开(公告)日：2025-02-18

申请号：US17421541

申请日：2019-01-15

Applicant: PULIKE BIOLOGICAL ENGINEERING, INC.

Inventor： Kegong Tian ,  Yan Xiao ,  Wenqiang Pang ,  Jinzhong Sun ,  Xuke Zhang

IPC: A61K39/135 ,  A61K39/00 ,  A61P31/14 ,  C07K14/005

Abstract: A type O foot-and-mouth disease virus-like particle antigen is provided, wherein the type O foot-and-mouth disease virus-like particle antigen is type O CATHAY topotype foot-and-mouth disease virus-like particle antigen, and the type O CATHAY topotype foot-and-mouth disease virus-like particle antigen is assembled by VP0, VP3 and VP1 antigen proteins of type O CATHAY topotype foot-and-mouth disease virus. The type O foot-and-mouth disease virus-like particle antigen has good immunogenicity. The prepared vaccine can produce complete protection against the O-type foot-and-mouth disease virus on the 14th day after immunization. The antibody titer produced is higher than that of the commercial inactivated vaccine, and the duration of immune protection can be maintained for at least 133 days. The prepared vaccine composition, preparation method and use thereof are also provided.

公开(公告)号：US20250051800A1

公开(公告)日：2025-02-13

申请号：US18915537

申请日：2024-10-15

Applicant: The Broad Institute, Inc. ,  President and Fellows of Harvard College ,  Massachusetts Institute of Technology

Inventor： Pardis Sabeti ,  Mohammadsharif Tabebordbar ,  Simon Ye

IPC: C12N15/86 ,  A61K31/7088 ,  A61K47/64 ,  A61K48/00 ,  C07K7/06 ,  C07K14/005 ,  C07K14/47 ,  C12N9/22 ,  C12N15/11

Abstract: Described herein are targeting moieties that can be capable of specifically targeting muscle cells and can include an n-mer motif. In some embodiments, the n-mer motif contains an RGD motif. Also described herein are vector systems, particles, polypeptides that can encode and/or contain one or more targeting moieties. Also described herein are methods of delivering a cargo to a cell, such as a muscle cell, using one or more of the targeting moieties described herein.

公开(公告)号：US20250042950A1

公开(公告)日：2025-02-06

申请号：US18719846

申请日：2023-02-16

Applicant: ZHEJIANG DIFFERENCE BIOLOGICAL TECHNOLOGY CO., LTD

Inventor： Ruiting CHEN ,  Huimin SUN ,  Shuihua MAO ,  Mengyun ZHOU ,  Jiasheng SONG

IPC: C07K14/005 ,  A61K39/00 ,  A61K39/215 ,  A61P31/14 ,  C12N7/00 ,  C12N15/86

Abstract: A recombinant protein for displaying an S protein of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), a recombinant virion, and a use thereof, as well as a recombinant gene expressing the S protein of the SARS-COV-2 are provided. The recombinant gene or the recombinant protein includes a sequence of an extracellular domain of the S protein of the SARS-COV-2 and sequences of a TMD and a CTD of an F protein of an avian paramyxovirus (APMV). The recombinant Newcastle disease virus (NDV) including this sequence has a strong ability to produce a neutralizing antibody. A recombinant gene or protein produced through the recombinant of a sequence encoding the extracellular domain of the S protein and sequences encoding the TMD and the CTD of the F protein of the APMV (except for NDV) has a great potential to become an excellent antigen candidate for Coronavirus Disease 2019 (COVID-19) vaccines.

公开(公告)号：US20250041402A1

公开(公告)日：2025-02-06

申请号：US18697359

申请日：2022-09-29

Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

Inventor： Peter PALESE ,  Florian KRAMMER ,  Adolfo GARCIA-SASTRE ,  Weina SUN

IPC: A61K39/215 ,  A61K39/00 ,  A61P37/04 ,  C07K14/005 ,  C12N7/00

Abstract: Described herein are recombinant Newcastle disease viruses (“NDVs”) comprising a packaged genome, wherein the packaged genome comprises a transgene comprising a nucleotide sequence encoding a protein comprising a SARS-CoV-2 delta variant spike protein or portion thereof. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises a SARS-CoV-2 delta variant spike protein ectodomain and NDV F protein transmembrane and cytoplasmic domains. The recombinant NDVs and compositions thereof are useful for the immunizing against SARS-CoV-2 delta variant as well as the prevention of COVID-19.

公开(公告)号：US20250041399A1

公开(公告)日：2025-02-06

申请号：US18792060

申请日：2024-08-01

Applicant: VIR BIOTECHNOLOGY, INC.

Inventor： Ann M. ARVIN ,  Eric BRUENING ,  Emily MARSHALL ,  Leah B. SORIAGA

IPC: A61K39/12 ,  A61K39/00 ,  A61P31/20 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86

Abstract: The disclosure relates to human papillomavirus (HPV) antigens and vectors for delivering the antigens. The disclosure also relates to immunogenic compositions comprising the same, and their uses.